Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Glucocorticoids in Pretreated B-CLL
NCT01576588Phase 2Completed
- Start
- Oct 2011
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic lymphocytic leukemia (CLL). Primary endpoint: Overall Response Rate at 3 months. Started Oct 2011; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01576588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01576588.